Objectives: We wished to determine the prognostic factors and the impact of initial empirical antibiotic therapy on the outcome of severe community-acquired pneumonia in patients without underlying co-morbid illness.
Methodology: This is a retrospective record review of consecutive patients with severe community-acquired pneumonia who were divided into those with and without underlying co-morbid illness.
Results: There were 182 patients including 112 primary (no co-morbid illness) and 70 secondary (underlying co-morbid illness) pneumonias. The overall mortality was 41.8% and there were no differences in APACHE II score or mortality when comparing cases with primary (37.5%) and secondary infections (48.6%). The mortality was significantly higher in patients with negative microbiology. Univariate analysis identified a number of parameters and various antibiotic regimens, which appeared to be associated with a significantly poorer outcome. On multivariate analysis multilobar pulmonary consolidation, need for mechanical ventilation, inotropes and dialysis were documented to be independent predictors of mortality. Only in their absence could different antibiotic regimens be shown to have an apparent impact on outcome and further analysis suggested that the reason for these differences related predominantly to differences in the severity of the infection.
Conclusions: Markers of disease severity appear to be the most important predictors of outcome in patients with severe community-acquired pneumonia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1440-1843.2001.00352.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical characteristics and risk factors for pneumonia in children.
Front Pediatr
December 2024
Department of Pediatrics, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Background: () is one of the most common pathogens of community-acquired pneumonia (CAP) in children. Although pneumonia (MPP) is considered a self-limiting disease, severe MPP (SMPP) occurs in some cases. This study aims to analyze clinical features of MPP and to explore predictive indicators in the early stage of infection.
View Article and Find Full Text PDFIncreased antimicrobial resistance of isolates obtained from children in Beijing, China, in 2023.
Front Cell Infect Microbiol
January 2025
Department of Bacteriology, Capital Institute of Pediatrics, Beijing, China.
Introduction: (), a common pathogen of community-acquired pneumonia in school-age children and adolescents, can cause epidemics worldwide. In late 2023, the incidence of infection among children reached a high level.
Methods: We investigated the antimicrobial susceptibility of 62 isolates obtained from children with pneumonia in Beijing between 2021 and 2023, and analyzed the correlation of antimicrobial susceptibility with molecular characteristics of isolates and clinical manifestations of patients.
Effused and Confused: A Case of Severe Adenovirus Pneumonia in a Teen.
Cureus
December 2024
Department of Respiratory Medicine, Faculty of Medicine, University of Thessaly, University General Hospital of Larissa, Larissa, GRC.
Adenovirus is a common pathogen responsible for respiratory infections, including pneumonia, predominantly in pediatric populations but also in immunocompromised adults. This case report details an 18-year-old immunocompetent male presenting with severe lobar pneumonia and pleural effusion, initially suggesting a bacterial origin. Despite antibiotic treatment, the patient's symptoms persisted, prompting further investigation.
View Article and Find Full Text PDFThe role of empiric atypical antibiotic coverage in non-severe community-acquired pneumonia.
Antimicrob Steward Healthc Epidemiol
December 2024
Division of Infectious Diseases, Veteran's Affairs Salt Lake City Health Care System, Salt Lake City, UT, USA.
A β-lactam plus a macrolide or a respiratory fluoroquinolone alone is recommended as standard empiric antibacterial therapy for non-severe adults hospitalized with community-acquired pneumonia (CAP) per Infectious Diseases Society of America guidelines. However, the evidence in support of adding empiric atypical antibacterial therapy, and specifically the addition of a macrolide, is conflicting and should be balanced with additional factors: the necessity of covering atypical organisms, benefits of macrolide-associated immunomodulation, harms associated with antibiotic use, and selection for antibiotic-resistant organisms. In this review, we examine the role of atypical coverage in standard treatment regimens for patients admitted with non-severe CAP and specifically focus on the addition of macrolides to β-lactams.
View Article and Find Full Text PDFEmploying a low-code machine learning approach to predict in-hospital mortality and length of stay in patients with community-acquired pneumonia.
Sci Rep
January 2025
Department of Pulmonology, Yokohama City University, Yokohama, Japan.
Community-acquired pneumonia (CAP) is associated with high mortality rates and often results in prolonged hospital stays. The potential of machine learning to enhance prediction accuracy in this context is significant, yet clinicians often lack the programming skills required for effective data mining. This study aimed to assess the effectiveness of a low-code approach for assisting clinicians with data mining for mortality and length of stay (LOS) prediction in patients with CAP.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!